Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Bartee

Showing results (11-20 of 50) with videos related to

Pageof 5
Sort By:
Journal for Immunotherapy of Cancer|January 18, 2019
Chimeric tumor modeling reveals role of partial PDL1 expression in resistance to virally induced immunotherapyMee Y Bartee, Parker C Dryja, Eric Bartee
Cancer Research|March 19, 2017
Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic VirotherapyMee Y Bartee, Katherine M Dunlap, Eric Bartee
Clinical Lymphoma, Myeloma & Leukemia|January 25, 2016
Myxoma Virus Induces Ligand Independent Extrinsic Apoptosis in Human Myeloma CellsMee Y Bartee, Katherine M Dunlap, Eric Bartee
Oncolytic Virotherapy|August 12, 2016
Myxoma virus attenuates expression of activating transcription factor 4 (ATF4) which has implications for the treatment of proteasome inhibitor-resistant multiple myelomaKatherine M Dunlap, Mee Y Bartee, Eric Bartee
Plos One|May 1, 2020
Reduced cellular binding affinity has profoundly different impacts on the spread of distinct poxvirusesErica B Flores, Mee Y Bartee, Eric Bartee
Virus Research|September 26, 2002
Immune evasion by a novel family of viral PHD/LAP-finger proteins of gamma-2 herpesviruses and poxvirusesKlaus Früh, Eric Bartee, Kristine Gouveia, et al.
Journal for Immunotherapy of Cancer|June 26, 2020
Initial dose of oncolytic myxoma virus programs durable antitumor immunity independent of in vivo viral replicationErica B Flores, Bulent A Aksoy, Eric Bartee
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 16, 2021
Inhibition of Polyamine Biosynthesis Using Difluoromethylornithine Acts as a Potent Immune Modulator and Displays Therapeutic Synergy With PD-1-blockadeParker Dryja, Carrie Fisher, Patrick M Woster, et al.
Journal for Immunotherapy of Cancer|June 3, 2023
Defects in intratumoral arginine metabolism attenuate the replication and therapeutic efficacy of oncolytic myxoma virusParker Dryja, Heather D Curtsinger, Mee Y Bartee, et al.
Molecular Therapy Oncolytics|December 10, 2016
Systemic therapy with oncolytic myxoma virus cures established residual multiple myeloma in miceEric Bartee, Mee Y Bartee, Bjarne Bogen, et al.
Pageof 5

Showing results (11-20 of 50) with videos related to

Sort By:
Pageof 5
Journal for Immunotherapy of Cancer|January 18, 2019
Chimeric tumor modeling reveals role of partial PDL1 expression in resistance to virally induced immunotherapyMee Y Bartee, Parker C Dryja, Eric Bartee
Cancer Research|March 19, 2017
Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic VirotherapyMee Y Bartee, Katherine M Dunlap, Eric Bartee
Clinical Lymphoma, Myeloma & Leukemia|January 25, 2016
Myxoma Virus Induces Ligand Independent Extrinsic Apoptosis in Human Myeloma CellsMee Y Bartee, Katherine M Dunlap, Eric Bartee
Oncolytic Virotherapy|August 12, 2016
Myxoma virus attenuates expression of activating transcription factor 4 (ATF4) which has implications for the treatment of proteasome inhibitor-resistant multiple myelomaKatherine M Dunlap, Mee Y Bartee, Eric Bartee
Plos One|May 1, 2020
Reduced cellular binding affinity has profoundly different impacts on the spread of distinct poxvirusesErica B Flores, Mee Y Bartee, Eric Bartee
Virus Research|September 26, 2002
Immune evasion by a novel family of viral PHD/LAP-finger proteins of gamma-2 herpesviruses and poxvirusesKlaus Früh, Eric Bartee, Kristine Gouveia, et al.
Journal for Immunotherapy of Cancer|June 26, 2020
Initial dose of oncolytic myxoma virus programs durable antitumor immunity independent of in vivo viral replicationErica B Flores, Bulent A Aksoy, Eric Bartee
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 16, 2021
Inhibition of Polyamine Biosynthesis Using Difluoromethylornithine Acts as a Potent Immune Modulator and Displays Therapeutic Synergy With PD-1-blockadeParker Dryja, Carrie Fisher, Patrick M Woster, et al.
Journal for Immunotherapy of Cancer|June 3, 2023
Defects in intratumoral arginine metabolism attenuate the replication and therapeutic efficacy of oncolytic myxoma virusParker Dryja, Heather D Curtsinger, Mee Y Bartee, et al.
Molecular Therapy Oncolytics|December 10, 2016
Systemic therapy with oncolytic myxoma virus cures established residual multiple myeloma in miceEric Bartee, Mee Y Bartee, Bjarne Bogen, et al.
Pageof 5